SYNLOGIC, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
SYNLOGIC, INC. (SYBX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$9.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-20.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2018-03-20
- SYNLOGIC, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2017-12-31 was -$7.00K.
- SYNLOGIC, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2017-09-30 was -$2.00K.
- SYNLOGIC, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2017 was -$9.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | -$9.00K derived: sum of 2 quarters · filed 2018-03-20 | -$9.00K 10-K · filed 2018-03-20 | |
| 2017-09-30 | -$2.00K 10-Q · filed 2017-11-13 | -$2.00K 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |